DE3427014A1 - Product for the prophylaxis and therapy of uncomplicated urinary tract infections - Google Patents
Product for the prophylaxis and therapy of uncomplicated urinary tract infectionsInfo
- Publication number
- DE3427014A1 DE3427014A1 DE19843427014 DE3427014A DE3427014A1 DE 3427014 A1 DE3427014 A1 DE 3427014A1 DE 19843427014 DE19843427014 DE 19843427014 DE 3427014 A DE3427014 A DE 3427014A DE 3427014 A1 DE3427014 A1 DE 3427014A1
- Authority
- DE
- Germany
- Prior art keywords
- urinary tract
- prophylaxis
- therapy
- tract infections
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Präparat zur Prophylaxe und Therapie unkomplizierterPreparation for prophylaxis and therapy less complicated
Harnwegsinfekte Die Erfindung betrifft ein Präparat zur Prophylaxe und T1le-apie unkomplizierter Harnwegsinfekte mit einem Gehalt an Preiselbeersaft.Urinary tract infections The invention relates to a preparation for prophylaxis and T1leapia of uncomplicated urinary tract infections containing cranberry juice.
Unkon,plizierte IIarnwegsinfekte stellen wegen ihrer verhältnismäßig großen Häufigkeit ein therapeutisches Problem dar, weil in den meisten Fällen die die Erreger unmittelbar angreifende Therapie mit chemotherapeutischen Präparaten und Antibiotica nicht geboten erscheint.Unconfirmed, complicated pathway infections are due to their relative proportions high frequency poses a therapeutic problem because in most cases the Therapy with chemotherapeutic preparations directly attacking the pathogens and antibiotics do not appear advisable.
Es hat sich gezeigt, daß für die Entstehung und Ausbreitung eines Harnwegsinfekts die Adhaesivität der bakteriellen Erreger am Uhergangsepithel des menschlichen und tierischen Harntraktes von erheblicher Bedeutung ist. Eine therapeutische Möglichkeit, die Entstehung und Ausbreitung von Harnwegsinfekten zu verhindern, besteht deshalb darin, die Adhaesivität von bakteriellen Erregern, überwiegen Kolibakterien, am Ubergangsepithel der Harnwege herabzusetzen. Es ist bekannt, daß Preiselbeersaft diese Wirkung der Herabsetzung der Adhaesivität hat (Sobota,A.E.: Inhibition oE bacterial adherence by cranberry juice: Potential use for the treatment of urinary tract infections. The J. of Urology, 131:1013, 1984). Diese Wirkung des Preiselbeersaftes allein ist aber noch verhältnismäßig gering.It has been shown that for the emergence and spread of a Urinary tract infection affects the adhesiveness of the bacterial pathogens to the urinary tract epithelium of the human and animal urinary tract is of considerable importance. A therapeutic one Possibility of preventing urinary tract infections from developing and spreading, therefore consists in the adhesiveness of bacterial pathogens, predominantly coli bacteria, on the transitional epithelium of the urinary tract. It is known that cranberry juice has this effect of reducing adhesiveness (Sobota, A.E .: Inhibition oE bacterial adherence by cranberry juice: Potential use for the treatment of urinary tract infections. The J. of Urology, 131: 1013, 1984). This effect of the cranberry juice but alone is still relatively small.
Aufgabe der Erfindung ist es daher, ein Präparat der eingangs genannten Gattung zu schaffen, das eine gesteigerte Wirkung bei wesentlicher Herabsetzung der Gefahr der Steinbildung hat.The object of the invention is therefore to provide a preparation of the types mentioned at the outset To create a genre that has an increased effect with a substantial reduction the risk of stone formation.
Es wurde überraschend gefunden, daß diese Aufgabe in zufriedenstellender Weise gelöst werden kann durch ein Präparat, das erfindungsgemäß 10 - 80 % Preiselbeersaft, 10 - 20 % Fructose, 0,1 - o,5 % Vitamin C und 0,05 - 0,2 % Magnesium entl-lält .It has surprisingly been found that this task is more satisfactory This can be solved by a preparation that, according to the invention, contains 10-80% cranberry juice, Contains 10-20% fructose, 0.1-0.5% vitamin C and 0.05-0.2% magnesium.
Durch die synergistische Wirkung der einzelnen Bestandteile des Präparats wird eine wesentliche Steigerung der Abwehr der die Adhaesivität von Bakterien am Ubergangsepithel des I1arntraletes herabsetzenden Wirkung erreicht. Deshalb sind für die gewünschte Wirkung bereits verhältnismäßig geringe Mengen ausreichend. Außerdem wird einer Veränderung des pH-Wertes des Urins und damit der Gefahr einer Steinbildung entgegengewirkt, so daß nicht nur eine Therapie, sondern auch eine Prophylaxe über verhältnismäßig lange Zeiträume unbedenklich möglich ist, ohne daß eine Steinbildung zu befürchten ist.Due to the synergistic effect of the individual components of the preparation becomes a substantial increase in the defense against the adhesiveness of bacteria Transitional epithelium of the intraletus has a lowering effect. That's why even relatively small amounts are sufficient for the desired effect. aside from that will change the pH of the urine and thus the risk of stone formation counteracted so that not just therapy, but also one Prophylaxis over relatively long periods of time is safely possible without stone formation is to be feared.
In Weiterbildung der Erfindung ist vorgesehen, daß das Präparat in einer bevorzugten Zusammensetzung 10 % Preiselbeersaft, 17 % Fructose, 0,1 % Vitamin C und 0,07% Magnesium enthält. Vorzuysweise werden als weitere Bestandteile 0,0001 - 0,0005 % Xaliumhydrogenkarbonat und 0,1 - 0,8 % Natriumchlorid zugegeben.In a further development of the invention it is provided that the preparation in a preferred composition 10% cranberry juice, 17% fructose, 0.1% vitamin C and 0.07% magnesium. As further components 0.0001 are preferred - 0.0005% xalium hydrogen carbonate and 0.1-0.8% sodium chloride added.
Diese Bestandteile wirken nicht nur geschmacksverbessernd, so daß auch bei längerer und umfangreicher Einnahme keine Ablehnung durch den Patienten erfolgt, sondern tragen wesentlich auch zu einer Normalisierung des pH-Wertes des Urins und damit zur Vermeidung von Steinbildungen bei.These ingredients not only have a taste-improving effect, so that no rejection by the patient even after long and extensive use takes place, but also contribute significantly to a normalization of the pH value of the Urine and thus to prevent stone formation.
Da die einzelnen Inhaltsstoffe bereits in der Literatur auf ihre Toxizität hin geprüft sind, sind toxische Systemwirkungen nicht zu erwarten. Außerdem ist die Allergenität dieser Stoffe gegenüber den bisher üblichen Harnwegstherapeutika einschließlich der sogenannten Harntees sehr gering.Since the individual ingredients are already in the literature for their toxicity have been tested, toxic system effects are not to be expected. Also is the allergenicity of these substances to the previously common urinary tract therapeutics including the so-called harntees, very low.
Gemäß einem bevorzugten Ausführungsbeispiel der Erfindung hat das Präparat zur Prophylaxe und Therapie unkomplizierter Harnwegsinfekte folgende Zusammensetzung: Preiselbeersaft 100,0 g Fructose 170,0 g Vitamin C 1,0 g Magnesium 0,7 g Kaliumhydrogenkarbonat 0,3 g Natrimchlorid 5,0 g - - Aqua bidestillata 723,0 g 1.000,0 g.According to a preferred embodiment of the invention that has Preparation for the prophylaxis and therapy of uncomplicated urinary tract infections with the following composition: Cranberry juice 100.0 g fructose 170.0 g vitamin C 1.0 g magnesium 0.7 g potassium hydrogen carbonate 0.3 g sodium chloride 5.0 g - - Aqua double distillata 723.0 g 1,000.0 g.
Dieses Präparat in flüssiger Darreichungsform kann in folgender Dosierung eingesetzt werden: J\kute unkomplizierte Cystitis: 3 mal 150,0 g per 24 Std., Prophylaxe rec. Cystitiden: abends 100,0 g; Prophylaxe ascend. unkomplizierter Harnwegsinfekte: 3 mal 100,0 g per 24 Std..This preparation in liquid dosage form can be used in the following dosage are used: J \ kute uncomplicated cystitis: 3 times 150.0 g per 24 hours, prophylaxis rec. Cystitis: in the evening 100.0 g; Prophylaxis ascending. uncomplicated urinary tract infections: 3 times 100.0 g per 24 hours.
Anstelle der flüssigen Darreichungsform kann das Präparat dui-ct Wasserentzug in Granulatform gebracht werden; aus diesem Granulat kann ein Tee der gleichen Zusammensetzung bereitet werden, eventuell unter Zusatz von Hippursäure.Instead of the liquid dosage form, the preparation dui-ct can dehydrate be brought into granulate form; These granules can be used to make a tea of the same composition can be prepared, possibly with the addition of hippuric acid.
Besondere Vorteile des Präparates liegen darin, daß es werden der fehlenden Nebenwirkungen und insbesondere der fel-llellden Toxizität der weitgehend natürlichen Bestandteije auch von denjenigen Patienten ohne Bedenken akzeptiert wird, die der Einnahme von chemotherapeutischen Präparaten tLnd/oder Antibiotica ablehnend oder zumindest skeptisch gegenüberstehen.Special advantages of the preparation are that it will be the lack of side effects and in particular the toxicity of the largely natural ingredients also accepted by those patients without hesitation will stop taking chemotherapeutic preparations tLnd / or antibiotics be negative or at least skeptical of it.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843427014 DE3427014A1 (en) | 1984-07-21 | 1984-07-21 | Product for the prophylaxis and therapy of uncomplicated urinary tract infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843427014 DE3427014A1 (en) | 1984-07-21 | 1984-07-21 | Product for the prophylaxis and therapy of uncomplicated urinary tract infections |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3427014A1 true DE3427014A1 (en) | 1986-01-23 |
Family
ID=6241280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19843427014 Ceased DE3427014A1 (en) | 1984-07-21 | 1984-07-21 | Product for the prophylaxis and therapy of uncomplicated urinary tract infections |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3427014A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474774A (en) * | 1994-03-25 | 1995-12-12 | Jlb, Inc. | Adhesion inhibiting composition |
US5525341A (en) * | 1992-10-09 | 1996-06-11 | Jlb, Inc. | Partially purified cranberry anti-adhesion activity |
US5646178A (en) * | 1992-10-09 | 1997-07-08 | Jlb, Inc. | Cranberry extract and biologically active compounds derived therefrom |
US5645994A (en) * | 1990-07-05 | 1997-07-08 | University Of Utah Research Foundation | Method and compositions for identification of species in a sample using type II topoisomerase sequences |
US5650432A (en) * | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
WO1997029763A1 (en) * | 1996-02-14 | 1997-08-21 | The Procter & Gamble Company | Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor |
US6210681B1 (en) | 1999-09-07 | 2001-04-03 | Jlb, Inc. | Plant proanthocyanidin extracts |
WO2004056380A2 (en) * | 2002-12-23 | 2004-07-08 | Forum Bioscience Holdings Limited | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
WO2005006891A1 (en) * | 2003-07-15 | 2005-01-27 | Forum Bioscience Holdings Limited | Carbohydrate substitute |
WO2009154608A1 (en) * | 2008-06-16 | 2009-12-23 | Hill's Pet Nutrition, Inc. | Composition for addition to drinking water |
EP2929873A1 (en) | 2014-04-07 | 2015-10-14 | Intermed S.A. | Skin cleansing compositions |
-
1984
- 1984-07-21 DE DE19843427014 patent/DE3427014A1/en not_active Ceased
Non-Patent Citations (2)
Title |
---|
LIST P.H., HÖRHAMMER L.: Hagers Handbuch der Pharmazeutischen Praxis, Bd.6, Teil C, 1979, S.373 * |
SOBOTA A.E.: The Journal of Urology, 131, S.1013 (1984) * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645994A (en) * | 1990-07-05 | 1997-07-08 | University Of Utah Research Foundation | Method and compositions for identification of species in a sample using type II topoisomerase sequences |
US5525341A (en) * | 1992-10-09 | 1996-06-11 | Jlb, Inc. | Partially purified cranberry anti-adhesion activity |
US5646178A (en) * | 1992-10-09 | 1997-07-08 | Jlb, Inc. | Cranberry extract and biologically active compounds derived therefrom |
US5474774A (en) * | 1994-03-25 | 1995-12-12 | Jlb, Inc. | Adhesion inhibiting composition |
EP0752871A1 (en) * | 1994-03-25 | 1997-01-15 | JLB, Inc. | Adhesion inhibiting composition |
EP0752871A4 (en) * | 1994-03-25 | 1998-10-21 | Jlb Inc | Adhesion inhibiting composition |
US5650432A (en) * | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
WO1997029763A1 (en) * | 1996-02-14 | 1997-08-21 | The Procter & Gamble Company | Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor |
US6210681B1 (en) | 1999-09-07 | 2001-04-03 | Jlb, Inc. | Plant proanthocyanidin extracts |
US6440471B2 (en) * | 1999-09-07 | 2002-08-27 | Jlb, Inc. | Plant proanthocyanidin extracts |
WO2004056380A2 (en) * | 2002-12-23 | 2004-07-08 | Forum Bioscience Holdings Limited | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
WO2004056380A3 (en) * | 2002-12-23 | 2004-09-16 | Forum Bioscience Holdings Ltd | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
WO2005006891A1 (en) * | 2003-07-15 | 2005-01-27 | Forum Bioscience Holdings Limited | Carbohydrate substitute |
WO2009154608A1 (en) * | 2008-06-16 | 2009-12-23 | Hill's Pet Nutrition, Inc. | Composition for addition to drinking water |
EP2929873A1 (en) | 2014-04-07 | 2015-10-14 | Intermed S.A. | Skin cleansing compositions |
WO2015154889A1 (en) | 2014-04-07 | 2015-10-15 | Intermed S.A. | Skin cleansing compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69109376T2 (en) | Inhibition of muscle loss and protein breakdown of muscles in mammals by tetracyclines. | |
DE3427014A1 (en) | Product for the prophylaxis and therapy of uncomplicated urinary tract infections | |
EP0125634A1 (en) | Use of a secretolytically active substance for the manufacture of a remedy against snoring and for combating snore phenomenon | |
DE2113215A1 (en) | Therapeutic compound | |
DE3011437A1 (en) | PHARMACEUTICAL AGENT FOR HEALING INFLAMMABLE AND / OR DEGENERATIVE AND / OR ATROPHIC MUSCULAR DISEASES | |
EP0476113A1 (en) | Medicament for treating hyperlipidaemia and/or atherosclerosis. | |
DE4028957C2 (en) | Therapeutic for the mouth area | |
DE2516027A1 (en) | Compsns for promoting protein synthesis and nitrogen conservation | |
DE3619426A1 (en) | AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION | |
DE3443242A1 (en) | Glycyrrhizin and a medicament containing an active compound | |
EP0349797B1 (en) | Stabilized pharmaceutical composition containing n-acetylcystein | |
EP0472033B1 (en) | 3,5-Diiod-L-thyronin for TSH-suppression and the treatment of goiter | |
DE1917283C3 (en) | Manufacture of antimicrobial preparations | |
DE19726871C1 (en) | Synergistic compositions for the selective control of tumor tissue | |
DE2715384C3 (en) | Medicines for diarrhea | |
DE69300037T2 (en) | Use of bucillamine in the manufacture of a medicament for the treatment of cystinuria. | |
EP0256353A2 (en) | Pharmaceutical therapy against the bad absorption of food or oral drugs | |
EP0265662A2 (en) | Pharmaceutic composition | |
DE2015877C3 (en) | Medicines used to treat prostate hypertrophy | |
Benz | 3. Die Kathepsinaktivität in normalen und malignen Geweben tumortragender Ratten | |
DE1467743A1 (en) | Process for the production of a preparation with extended vitamin B 12 effect | |
DE60218427T2 (en) | METHOD FOR OBTAINING AN ISOLATED EXTRACT FROM THE PLANT CYCLAMEN EUROPAEUM L. AND ITS USE AS A THERAPEUTIC AGENT | |
DE69919040T2 (en) | USE OF A SYNERGISTIC COMPOSITION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF LIVER DISEASES | |
DE3439805C2 (en) | Use of arginine aspartate for the treatment of hypotrophy | |
EP0291751B1 (en) | Pharmaceutical mixture preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8131 | Rejection |